Molecular mechanisms of semaglutide and liraglutide as a therapeutic option for obesity, Frontiers in Nutrition (2024) Obesity and comorbid conditions, StatPearls (2024) FDA approves generic liraglutide to address GLP-1 drug shortage, Journal of the American Medical Association (2024) Annual report, Novo Nordisk (2024) Liraglutide for weight management: a critical review of the evidence, Obesity Science & Practice (2016) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study, International Journal of Obesity (2013) Real-world clinical effectiveness of liraglutide for weight management in Trkiye: insights from the LIRA-TR study, Journal of Clinical Medicine (2024) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA Network Open (2022) Efficacy of semaglutide in treating obesity: a systematic review of randomized controlled trials (RCTs), Cureus (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Journal of Medicine (2021) Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial, Nature Medicine (2024) Oral semaglutide versus empagliflozin in patients with Type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial, Diabetes Care (2019) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial, Journal of the American Medical Association (2022) One-year weight reduction with semaglutide or liraglutide in clinical practice, JAMA Network Open (2024) Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis, Obesity (2023) Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis, Frontiers in Pharmacology (2025) Comparing the efficacy of liraglutide and semaglutide on weight loss: Experience from the Middle East Gulf region and literature review, Hospital Pharmacy (2025) Saxenda label, DailyMed (2025) Ozempic label, DailyMed (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
This is the most concentrated option and works well when you want smaller injection volumes
The first dual GIP/GLP-1 receptor agonist, NNC0090-2746 (also known as RG7697, RO6811135, or MAR709), is a 40-amino acid peptide acylated with a C16:0 fatty acid to lysine residue at position 40 [ Figure 2 , Table 1 ]
Side effects should largely resolve within the first two to four weeks
Dihexa was administered to the APP/PS1 mice intraperitoneally from 6 to 9 months of age and 0.9% saline was administered to the wild type group once per day over a three month time period
